Elhence Anshuman, Vaishnav Manas, Kumar Ramesh, Pathak Piyush, Soni Kapil Dev, Aggarwal Richa, Soneja Manish, Jorwal Pankaj, Kumar Arvind, Khanna Puneet, Singh Akhil Kant, Biswas Ashutosh, Nischal Neeraj, Dar Lalit, Choudhary Aashish, Rangarajan Krithika, Mohan Anant, Acharya Pragyan, Nayak Baibaswata, Gunjan Deepak, Saraya Anoop, Mahapatra Soumya, Makharia Govind, Trikha Anjan, Garg Pramod
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110 029, India.
Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801 507, India.
Indian J Gastroenterol. 2020 Jun;39(3):285-291. doi: 10.1007/s12664-020-01074-3. Epub 2020 Aug 15.
There is a paucity of data on the clinical presentations and outcomes of Corona Virus Disease-19 (COVID-19) in patients with underlying liver disease. We aimed to summarize the presentations and outcomes of COVID-19-positive patients and compare with historical controls.
Patients with known chronic liver disease who presented with superimposed COVID-19 (n = 28) between 22 April 2020 and 22 June 2020 were studied. Seventy-eight cirrhotic patients without COVID-19 were included as historical controls for comparison.
A total of 28 COVID-19 patients (two without cirrhosis, one with compensated cirrhosis, sixteen with acute decompensation [AD], and nine with acute-on-chronic liver failure [ACLF]) were included. The etiology of cirrhosis was alcohol (n = 9), non-alcoholic fatty liver disease (n = 2), viral (n = 5), autoimmune hepatitis (n = 4), and cryptogenic cirrhosis (n = 6). The clinical presentations included complications of cirrhosis in 12 (46.2%), respiratory symptoms in 3 (11.5%), and combined complications of cirrhosis and respiratory symptoms in 11 (42.3%) patients. The median hospital stay was 8 (7-12) days. The mortality rate in COVID-19 patients was 42.3% (11/26), as compared with 23.1% (18/78) in the historical controls (p = 0.077). All COVID-19 patients with ACLF (9/9) died compared with 53.3% (16/30) in ACLF of historical controls (p = 0.015). Mortality rate was higher in COVID-19 patients with compensated cirrhosis and AD as compared with historical controls 2/17 (11.8%) vs. 2/48 (4.2%), though not statistically significant (p = 0.278). Requirement of mechanical ventilation independently predicted mortality (hazard ratio 13.68). Both non-cirrhotic patients presented with respiratory symptoms and recovered uneventfully.
COVID-19 is associated with poor outcomes in patients with cirrhosis, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.
关于合并基础肝病的2019冠状病毒病(COVID-19)患者的临床表现和预后的数据匮乏。我们旨在总结COVID-19阳性患者的表现和预后,并与历史对照进行比较。
对2020年4月22日至2020年6月22日期间出现COVID-19叠加感染的已知慢性肝病患者(n = 28)进行研究。78例无COVID-19的肝硬化患者作为历史对照纳入研究以进行比较。
共纳入28例COVID-19患者(2例无肝硬化,1例为代偿期肝硬化,16例为急性失代偿期[AD],9例为慢加急性肝衰竭[ACLF])。肝硬化的病因包括酒精性(n = 9)、非酒精性脂肪性肝病(n = 2)、病毒性(n = 5)、自身免疫性肝炎(n = 4)和隐源性肝硬化(n = 6)。临床表现包括12例(46.2%)的肝硬化并发症、3例(11.5%)的呼吸道症状以及11例(42.3%)的肝硬化和呼吸道症状合并并发症。中位住院时间为8(7 - 12)天。COVID-19患者的死亡率为42.3%(11/26),而历史对照的死亡率为23.1%(18/78)(p = 0.077)。所有ACLF的COVID-19患者(9/9)均死亡,而历史对照的ACLF患者死亡率为53.3%(16/30)(p = 0.015)。与历史对照相比,代偿期肝硬化和AD的COVID-19患者死亡率更高,分别为2/17(11.8%)和2/48(4.2%),尽管差异无统计学意义(p = 0.278)。机械通气需求可独立预测死亡率(风险比13.68)。2例非肝硬化患者均出现呼吸道症状且康复顺利。
COVID-19与肝硬化患者的不良预后相关,ACLF患者的生存率最差。机械通气与不良预后相关。